Zobrazeno 31 - 40
of 520
pro vyhledávání: '"Jeffrey W. Clark"'
Autor:
Rakesh K. Jain, David P. Ryan, Charles S. Fuchs, Rebecca Miksad, Jeffrey W. Clark, Emmanuelle di Tomaso, Marek Ancukiewicz, Dan G. Duda, Andrew X. Zhu
Supplementary Tables S1-S7.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a53f9f9e17dc340c0381656e79f53404
https://doi.org/10.1158/1078-0432.22440924.v1
https://doi.org/10.1158/1078-0432.22440924.v1
Autor:
Ryan B. Corcoran, Genevieve M. Boland, AmirAli Talasaz, Victoria M. Raymond, James C. Cusack, Rocco Ricciardi, David Berger, Hiroko Kunitake, Motaz Qadan, Cristina R. Ferrone, Liliana Bordeianou, Theodore S. Hong, Jennifer Y. Wo, Colin D. Weekes, David P. Ryan, Eric J. Roeland, Ryan D. Nipp, Samuel J. Klempner, Lipika Goyal, Bruce J. Giantonio, Joseph W. Franses, Jon S. Dubois, Jeffrey W. Clark, Lawrence S. Blaszkowsky, Jill N. Allen, Heather A. Shahzade, Isobel J. Fetter, Yojan S. Shah, Islam Baiev, Joy Jarnagin, Nihaarika Sharma, John H. Carmichael, Susannah Phillips, Benchun Miao, Kathryn D. Fosbenner, Madeleine G. Fish, Katie Kanter, Yupeng He, Ariel Jaimovich, Anna V. Hartwig, Giulia Siravegna, Emily E. Van Seventer, Aparna R. Parikh
Purpose:Detection of persistent circulating tumor DNA (ctDNA) after curative-intent surgery can identify patients with minimal residual disease (MRD) who will ultimately recur. Most ctDNA MRD assays require tumor sequencing to identify tumor-derived
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b5329c2a17c452869d41a1978c4f354
https://doi.org/10.1158/1078-0432.c.6530634
https://doi.org/10.1158/1078-0432.c.6530634
Autor:
Andrew X. Zhu, David P. Ryan, Leif W. Ellisen, David P. Schenkein, Sam Agresta, Kimberly S. Straley, Nabeel Bardeesy, Kenneth K. Tanabe, Cristina R. Ferrone, Jennifer Y. Wo, Theodore S. Hong, Supriya K. Saha, Janet E. Murphy, Lawrence S. Blaszkowsky, Jill N. Allen, Jeffrey W. Clark, Eunice L. Kwak, A. John Iafrate, Jason E. Faris, Katharine Yen, Hyeryun Kim, Hua Yang, Hannah M. Liebman, David C. Christiani, Vikram Deshpande, Marek Ancukiewicz, Ronnie T. Poon, Thomas Yau, Lipika Goyal, Darrell R. Borger
PDF file - 104KB, Clinical features of IDH1-mutant intrahepatic cholangiocarcinoma patients in the Screening cohort.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43bac6ecbee16339e3de1293f2ad4a6e
https://doi.org/10.1158/1078-0432.22451924.v1
https://doi.org/10.1158/1078-0432.22451924.v1
Autor:
Rakesh K. Jain, Yves Boucher, Cristina R. Ferrone, James Michaelson, Ronald M. Evans, Michael Downes, Carlos Fernandez-del Castillo, Keith D. Lillemoe, Vikram Deshpande, David P. Ryan, Janet E. Murphy, Jeffrey W. Clark, Theodore S. Hong, Andrea Zanconato, Daniella Dias-Santos, Theodoros Michelakos, Alex Jacobson, Jonathan A. Crain, William W. Ho, Kohei Shigeta, Hang Lee, Joao Incio, Matthias Pinter, Kamila Naxerova, Hao Liu
Supplementary table and figure legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::017e10a0fa8c622adf2c1e933453d86b
https://doi.org/10.1158/1078-0432.22466738
https://doi.org/10.1158/1078-0432.22466738
Autor:
Ryan B. Corcoran, Jeffrey W. Clark, Nora Horick, Giulia Siravegna, Theodore S. Hong, Jochen K. Lennerz, A. John Iafrate, Dora Dias-Santagata, Andrew X. Zhu, Jennifer Y. Wo, Colin D. Weekes, Eric Roeland, Ryan D. Nipp, Lipika Goyal, Bruce Giantonio, David P. Ryan, Lawrence S. Blaszkowsky, Jill N. Allen, Heather A. Shahzade, Brandon Nadres, Kathryn Fosbenner, Bezaye Teshome, Madeleine G. Fish, Ashraf Thabet, Isobel J. Fetter, Emily E. Van Seventer, Katie Kanter, Jaime L. Schneider, Amikasra Mojtahed, Aparna R. Parikh
Supplementary Table S2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::816d9f85d147496ca6dcc499a2697fc4
https://doi.org/10.1158/1078-0432.22479813.v1
https://doi.org/10.1158/1078-0432.22479813.v1
Autor:
James M. Cleary, Jason L. Hornick, Marios Giannakis, Kimmie Ng, Brian M. Wolpin, Andrew D. Cherniack, Jeffrey A. Meyerhardt, Matthew L. Meyerson, Ewa Sicinska, Azra H. Ligon, Laura E. MacConaill, Matthew H. Kulke, Rahul Gujrathi, George D. Demetri, Jessica J. Lin, Anna F. Farago, Jeffrey W. Clark, Cheta Siletti, Rachel B. Keller, Geoffrey I. Shapiro, Aaron R. Thorner, Matthew D. Ducar, Anwesha Nag, Lauren K. Brais, Emma Reilly, Ritika Abhyankar, Atul B. Shinagare, Liam F. Spurr, Yvonne Y. Li, Harshabad Singh
Supplementary Figure 1. Pan-TRK IHC in four cases identified as having NTRK fusions by OncoPanel analysis shows strong cytoplasmic staining confirming the presence of functional TRK fusion protein (40Ã-). Top left image demonstrates the specificity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::139065af195777f2bf3a4bb3c605af7f
https://doi.org/10.1158/1078-0432.22481535
https://doi.org/10.1158/1078-0432.22481535
Autor:
Rakesh K. Jain, Yves Boucher, Cristina R. Ferrone, James Michaelson, Ronald M. Evans, Michael Downes, Carlos Fernandez-del Castillo, Keith D. Lillemoe, Vikram Deshpande, David P. Ryan, Janet E. Murphy, Jeffrey W. Clark, Theodore S. Hong, Andrea Zanconato, Daniella Dias-Santos, Theodoros Michelakos, Alex Jacobson, Jonathan A. Crain, William W. Ho, Kohei Shigeta, Hang Lee, Joao Incio, Matthias Pinter, Kamila Naxerova, Hao Liu
Genes differentially expressed in ACEi alone treated group compared to control group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5c24328e783a028078f0649ae1c15c1
https://doi.org/10.1158/1078-0432.22466747
https://doi.org/10.1158/1078-0432.22466747
Autor:
Andrew X. Zhu, Dan G. Duda, Rakesh K. Jain, Kohei Shigeta, Emilie Mamessier, Tai Hato, Eileen Regan, Caroline F. Dinicola, Anthony J. Afflitto, Aralee Galway, Michelle Knowles, Alona Muzikansky, Avinash Kambadakone, Jeffrey W. Clark, Matthew B. Yurgelun, Jill N. Allen, Andrea J. Bullock, Rebecca Miksad, Thomas A. Abrams, Hui Zheng, Lipika Goyal
Purpose:Sorafenib is a standard first-line treatment for advanced hepatocellular carcinoma (HCC). The phase III SHARP trial showed a median time-to-progression (mTTP) of 5.5 months, overall response rate (ORR) of 2%, and median overall survival (mOS)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae7e2b43bbbedb01a8b5b498b8558469
https://doi.org/10.1158/1078-0432.c.6528783
https://doi.org/10.1158/1078-0432.c.6528783
Autor:
Ryan B. Corcoran, Jeffrey W. Clark, Nora Horick, Giulia Siravegna, Theodore S. Hong, Jochen K. Lennerz, A. John Iafrate, Dora Dias-Santagata, Andrew X. Zhu, Jennifer Y. Wo, Colin D. Weekes, Eric Roeland, Ryan D. Nipp, Lipika Goyal, Bruce Giantonio, David P. Ryan, Lawrence S. Blaszkowsky, Jill N. Allen, Heather A. Shahzade, Brandon Nadres, Kathryn Fosbenner, Bezaye Teshome, Madeleine G. Fish, Ashraf Thabet, Isobel J. Fetter, Emily E. Van Seventer, Katie Kanter, Jaime L. Schneider, Amikasra Mojtahed, Aparna R. Parikh
Supplementary Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76a6d960703bcb18614f6e600c4de860
https://doi.org/10.1158/1078-0432.22479819
https://doi.org/10.1158/1078-0432.22479819
Autor:
Rakesh K. Jain, David P. Ryan, Charles S. Fuchs, Rebecca Miksad, Jeffrey W. Clark, Emmanuelle di Tomaso, Marek Ancukiewicz, Dan G. Duda, Andrew X. Zhu
Purpose: Sunitinib—a multitargeted tyrosine kinase inhibitor—can modulate circulating inflammatory factors in cancer patients that may be relevant for hepatocellular carcinoma (HCC) progression. However, a recent phase III study of sunitinib in H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::414c01594173188032f370361f4f0c56
https://doi.org/10.1158/1078-0432.c.6518151
https://doi.org/10.1158/1078-0432.c.6518151